Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin

International Journal of Cardiology

Volumn 167, Issue 2, 2013, Pages 430-435

  Siller Matula, Jolanta M ^a   Delle Karth, Georg ^a   Christ, Günter ^b   Neunteufl, Thomas ^a   Maurer, Gerald ^a   Huber, Kurt ^c   Tolios, Alexander ^a   Drucker, Christa ^a   Jilma, Bernd ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b KAISER FRANZ JOSEF HOSPITAL   (Austria)

^c Wilhelminenhospital   (Austria)

Author keywords

Aspirin; Cardiac adverse event; Clopidogrel; Diabetes mellitus; MEA; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CLOPIDOGREL; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTON PUMP INHIBITOR;

ACUTE CORONARY SYNDROME; ADULT; ANTICOAGULANT THERAPY; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIABETES MELLITUS; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LEUKOCYTE COUNT; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PREDICTION; PRIORITY JOURNAL; STENT; STENT THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT OUTCOME;

AGED; ASPIRIN; CARDIOVASCULAR DISEASES; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84879099050     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.01.016     Document Type: Article

References (53)

1. T. Geisler, D. Grass, and B. Bigalke The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score J Thromb Haemost 6 1 2008 54 61
2. J.M. Siller-Matula, J. Krumphuber, and B. Jilma Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular disease Br J Pharmacol 159 3 2009 502 517
3. P.A. Gurbel, U.S. Tantry, A.R. Shuldiner, and D.J. Kereiakes Genotyping: one piece of the puzzle to personalize antiplatelet therapy J Am Coll Cardiol 56 2 2010 112 116
4. M. Kozinski, L. Bielis, and J. Wisniewska-Szmyt Diurnal variation in platelet inhibition by clopidogrel Platelets 22 8 2011 579 587
5. M. Kozinski, L. Bielis, and J. Wisniewska-Szmyt Increased morning ADP-dependent platelet aggregation persists despite dual antiplatelet therapy in patients with first ST-segment elevation myocardial infarction: preliminary report Cardiol J 15 6 2008 530 536
6. A.D. Michelson, M. Cattaneo, and J.W. Eikelboom Aspirin resistance: position paper of the Working Group on Aspirin Resistance J Thromb Haemost 3 6 2005 1309 1311
7. M. Kasprzak, M. Kozinski, and L. Bielis Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome Cardiol J 16 6 2009 535 544
8. T. Geisler, C. Zurn, and R. Simonenko Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions Eur Heart J 31 1 2010 59 66
9. J. Siller-Matula, K. Schror, J. Wojta, and K. Huber Thienopyridines in cardiovascular disease: focus on clopidogrel resistance Thromb Haemost 97 3 2007 385 393
10. A.L. Frelinger III, A.D. Michelson, and S.D. Wiviott Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44 Thromb Haemost 106 2 2011
11. P.A. Gurbel Tantry US: clopidogrel response variability and the advent of personalised antiplatelet therapy. A bench to bedside journey Thromb Haemost 106 2 2011
12. A. Kubica, M. Kozinski, G. Grzesk, T. Fabiszak, E.P. Navarese, and A. Goch Genetic determinants of platelet response to clopidogrel J Thromb Thrombolysis 32 4 2011 459 466
13. I. Tentzeris, J. Siller-Matula, S. Farhan, R. Jarai, J. Wojta, and K. Huber Platelet function variability and non-genetic causes Thromb Haemost 105 Suppl. 1 2011 S60 S66
14. J.M. Siller-Matula, I. Lang, G. Christ, and B. Jilma Calcium-channel blockers reduce the antiplatelet effect of clopidogrel J Am Coll Cardiol 52 19 2008 1557 1563
15. L. Yukhanyan, M.K. Freynhofer, J. Siller-Matula, K. Schror, and K. Huber Genetic variability in response to clopidogrel therapy and its clinical implications Thromb Haemost 105 Suppl. 1 2011 S55 S59
16. J.M. Siller-Matula, B. Jilma, K. Schror, G. Christ, and K. Huber Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis J Thromb Haemost 8 12 2010 2624 2641
17. J.M. Siller-Matula, A.O. Spiel, I.M. Lang, G. Kreiner, G. Christ, and B. Jilma Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel Am Heart J 157 1 2009 148.e1 148.e5
18. M. Crescente, A. Di Castelnuovo, L. Iacoviello, J. Vermylen, C. Cerletti, and G. de Gaetano Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100 Thromb Haemost 99 2008 14 26
19. B.T. Ivandic, E. Giannitsis, P. Schlick, P. Staritz, H.A. Katus, and T. Hohlfeld Determination of aspirin responsiveness by use of whole blood platelet aggregometry Clin Chem 53 4 2007 614 619
20. M. Cattaneo Resistance to anti-platelet agents Thromb Res 127 Suppl. 3 2011 S61 S63
21. M. Wurtz, E.L. Grove, and L.N. Wulff Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets JACC Cardiovasc Interv 3 8 2010 828 835
22. N.J. Breet, J.W. van Werkum, and H.J. Bouman High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention Heart 97 12 2011 983 990
23. T. Geisler, K. Mueller, and S. Aichele Impact of inflammatory state and metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI: prognostic relevance of residual platelet aggregability in diabetics undergoing coronary interventions Clin Res Cardiol 99 11 2010 743 752
24. J.M. Siller-Matula, G. Gouya, M. Wolzt, and B. Jilma Cross validation of the multiple electrode aggregometry Thromb Haemost 102 2 2009 397 403
25. J.M. Siller-Matula, G. Christ, I.M. Lang, G. Delle-Karth, K. Huber, and B. Jilma Multiple electrode aggregometry predicts stent thrombosis better than the VASP assay J Thromb Haemost 8 2 2010 351 359
26. D.E. Cutlip, S. Windecker, and R. Mehran Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 17 2007 2344 2351
27. J.D. Snoep, M.M. Hovens, J.C. Eikenboom, J.G. van der Bom, J.W. Jukema, and M.V. Huisman Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis Am Heart J 154 2 2007 221 231
28. E.I. Lev, R.T. Patel, and K.J. Maresh Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance J Am Coll Cardiol 47 1 2006 27 33
29. A.M. Gori, R. Marcucci, and A. Migliorini Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents J Am Coll Cardiol 52 9 2008 734 739
30. P. Eshtehardi, S. Windecker, and S. Cook Dual low response to acetylsalicylic acid and clopidogrel is associated with myonecrosis and stent thrombosis after coronary stent implantation Am Heart J 159 5 2010 891 898 e1
31. P.A. Gum, K. Kottke-Marchant, P.A. Welsh, J. White, and E.J. Topol A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease J Am Coll Cardiol 41 6 2003 961 965
32. A.L. Frelinger III, Y. Li, and M.D. Linden Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization Circulation 120 25 2009 2586 2596
33. J.W. Eikelboom, J. Hirsh, J.I. Weitz, M. Johnston, Q. Yi, and S. Yusuf Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events Circulation 105 14 2002 1650 1655
34. G. Krasopoulos, S.J. Brister, W.S. Beattie, and M.R. Buchanan Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis BMJ 336 7637 2008 195 198
35. E.I. Lev, A. Solodky, and N. Harel Treatment of aspirin-resistant patients with omega-3 fatty acids versus aspirin dose escalation J Am Coll Cardiol 55 2 2010 114 121
36. H. Neubauer, A.F. Kaiser, and H.G. Endres Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance - the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy BMC Med 9 2011 3
37. M.J. Price, P.B. Berger, and P.S. Teirstein Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial JAMA 305 11 2011 1097 1105
38. S.D. Wiviott, E. Braunwald, and C.H. McCabe Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 20 2007 2001 2015
39. D. Sibbing, S. Braun, and T. Morath Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis J Am Coll Cardiol 53 2009 849 856
40. R. Marcucci, A.M. Gori, and R. Paniccia Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up Circulation 119 2 2009 237 242
41. G. Lemesle, C. Delhaye, and A. Sudre Impact of high loading and maintenance dose of clopidogrel within the first 15 days after percutaneous coronary intervention on patient outcome Am Heart J 157 2 2009 375 382
42. D.J. Angiolillo, E. Bernardo, and M. Sabate Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease J Am Coll Cardiol 50 16 2007 1541 1547
43. L. Ang, V. Palakodeti, and A. Khalid Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel J Am Coll Cardiol 52 13 2008 1052 1059
44. T. Cuisset, C. Frere, and J. Quilici Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response Thromb Res 123 4 2008 597 603
45. D.J. Angiolillo, E. Bernardo, and M. Zanoni Impact of insulin receptor substrate-1 genotypes on platelet reactivity and cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease J Am Coll Cardiol 58 1 2011 30 39
46. J. DiChiara, K.P. Bliden, and U.S. Tantry The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study Diabetes 56 12 2007 3014 3019
47. P. Fontana, P. Berdague, and C. Castelli P DEM, Reny JL: clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study J Thromb Haemost 8 12 2010 2614 2623
48. K. Muller, S. Aichele, and M. Herkommer Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease Atherosclerosis 213 1 2010 256 262
49. P.A. Gurbel, K.P. Bliden, and U.S. Tantry Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study J Am Coll Cardiol 48 11 2006 2186 2191
50. A.M. Gori, F. Cesari, and R. Marcucci The balance between pro- and anti-inflammatory cytokines is associated with platelet aggregability in acute coronary syndrome patients Atherosclerosis 202 1 2009 255 262
51. U. Derhaschnig, D. Bergmair, C. Marsik, I. Schlifke, J. Wijdenes, and B. Jilma Effect of interleukin-6 blockade on tissue factor-induced coagulation in human endotoxemia Crit Care Med 32 5 2004 1136 1140
52. G. Campo, G. Parrinello, and P. Ferraresi Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome J Am Coll Cardiol 57 25 2011 2474 2483
53. J.M. Siller-Matula, K. Haberl, K. Prillinger, S. Panzer, I. Lang, and B. Jilma The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation Thromb Res 123 6 2009 874 880